Data on measles incidence, acute case fatality, and delayed mortality were collected on 25,443 children aged 0-95 months during the course of a community-based, double-blind, placebo-controlled, randomized trial of vitamin A supplementation in rural, northern Ghana between 1989 and 1991. Measles vaccine coverage in these children was 48%. The overall estimated measles incidence rate was 24.3 per 1,000 child-years, and acute case fatality was 15.7%. There was not significantly increased mortality in survivors of the acute phase of measles compared with controls (rate ratio =1.22, 95% confidence interval (Cl) 0.65-2.30). Reported incidence rates and case fatality were higher in families with low paternal education, in the dry season, and in unvaccinated children, and case fatality was higher in malnourished children. There was no sex difference in incidence, but acute case fatality was somewhat higher in girls than boys (adjusted odds ratio = 1.3, 95% Cl 0.9-2.1). Measles incidence was lower in vitamin A-supplemented groups (23.6 per 1,000 child-years) than in placebo groups (28.9 per 1,000 child-years), but this difference was not statistically significant (p = 0.33). Among 946 measles cases in clusters randomized to receive vitamin A or placebo, there was no marked difference in acute measles case fatality between vitamin A-supplemented and placebo groups (15.4% vs. 14.5%, respectively). The biologic effects of vitamin A supplementation on the subsequent clinical manifestations and severity of measles need further elucidation. Am J Epidemiol 1997; 146:646-54. measles; measles vaccine; mortality; risk assessment; vitamin A Measles is a major cause of child mortality in developing countries (1). Case fatality ratios of up to 20 percent have been found in community studies in West Africa (2). Measles has also been reported to increase morbidity (3, 4) and mortality (5, 6) and to worsen nutritional status (3, 7) for several months after the acute episode.
Measles is a major cause of child mortality in developing countries (1) . Case fatality ratios of up to 20 percent have been found in community studies in West Africa (2) . Measles has also been reported to increase morbidity (3, 4) and mortality (5, 6) and to worsen nutritional status (3, 7) for several months after the acute episode.
Vitamin A treatment of measles reduces acute case fatality. A combined analysis of three randomized controlled trials (8) (9) (10) ) among children hospitalized with measles showed a 66 percent reduction (95 percent confidence interval (Cl) 23 to 85) in acute fatality among children who were treated with vitamin A (11) . Population-based trials of vitamin A supplementation have shown an average overall decrease in all-cause child mortality of 23 percent (95 percent Cl 12 to 32) (12) and a 26 percent reduction (95 percent Cl -4 to 47) in measles-associated mortality (13) , though the latter was not statistically significant. The effect of population-based vitamin A supplementation on acute measles case fatality has not been studied previously.
We report a community-based study in northern Ghana in which acute measles case fatality and delayed mortality (deaths after the acute phase of measles) were studied, together with factors associated with measles incidence and case fatality, including the effect of supplementation with vitamin A.
MATERIALS AND METHODS Study site
The study took place in the Kassena-Nankana district of the Upper East Region of Ghana, in the guinea savannah bordering Burkina Faso. The area has a sub-Sahelian climate and a single annual rainy season from May to October. The population lives in dispersed compounds where extended families live in a group of interconnected houses. The district has one hospital and three health centers, serving a total population of 180,000.
The study methods have been described in detail elsewhere (13) . In brief, the population of a geograph-Measles Incidence, Case Fatality, Vitamin A in Ghana 647 ically defined, rural area within the district was censused in mid-1989. The study area was divided into 185 small geographic units, each comprising 30-77 compounds (mean, 51). The units were randomized to receive either vitamin A or placebo every 4 months for 2 years. All children who had been born between 1984 and 1989 were identified in a house-to-house census, and additional children (either new births or children who moved into a compound to stay for at least 4 months) were registered throughout the study period during home visits every 4 months. Children were included in the trial and supplemented with vitamin A or placebo if they were aged 6 months or more at the time of the interviewer's visit. To assess measles vaccination coverage, incidence, and fatality, all registered children were included in the analyses.
Data collection
At enrollment, the dates of birth of children and their mothers were assessed using local events calendars, supplemented by any documentation available. Information on the number of dead and surviving siblings, parents' education, and mother's age was sought from the mother or guardian of each child, and vaccination status details were abstracted from the home-based vaccination record. In each compound, the type of roofing and possession of a radio or bicycle were noted. Children were weighed to the nearest 100 g using 25-kg Salter hanging scales (CMS Weighing Equipment, High Holborn, London, United Kingdom), and their mid-upper arm circumference was measured to the nearest millimeter with an insertion tape.
Fieldworkers visited children every 4 months for 2 years, in seven survey rounds. Those aged 6 months or over at a visit were given a dose of vitamin A (100,000 IU of retinol equivalent for children aged 6-11 months or 200,000 IU for older children) or placebo. Children were recorded as "present," "temporarily absent," "moved away," or "died" at each of these visits. At each round, information was obtained on illnesses within the past week, the child's weight, and left mid-upper arm circumference and, from the second dosing round, on hospitalization or measles since the last visit. In the first data collection round, information was obtained on whether each child had ever been hospitalized or had ever had measles.
Child deaths were identified at the time of the home visits each 4 months and, independently, through a network of approximately 100 community "key informants." Using a standard procedure, trained staff interviewed the nearest relative of all study children who died, within a few months of the death, to obtain details of the circumstances, symptoms, and signs preceding the death. These "verbal autopsies" were examined independently by three physicians (D. A. R., F. N. B., and A. Hall of the London School of Hygiene and Tropical Medicine), and each physician assigned the cause of death to one of 11 categories. If at least two of the physicians assigned the death to the same category, this was taken as the cause of death; otherwise, it was coded as unknown. There was agreement among all three clinicians in assigning the cause of death as measles for 134 children and between two clinicians for 17 deaths. A further 16 deaths were coded as measles by only one clinician and were not included as measles deaths in this analysis.
Information on vaccination status was updated annually from the home-based vaccination records. Children with no record of measles vaccination on the card and those with no vaccination card were classified as unvaccinated. For children who died, an attempt was made to update information on vaccination at the verbal autopsy interview, but the vaccination record was available in only 15 percent of these interviews because of the local practice of burning a person's possessions soon after death.
Data were available for the present analyses from September-December 1989 (round one) to SeptemberDecember 1991 (round seven). Altogether, 25,666 children were registered as study children, of whom 25,443 had information collected on whether they had had measles in the previous 4 months to be included in the analyses described below.
Data analysis
Measles incidence. Children were classified as measles cases if, at a fieldworker's visit, they were reported to have had measles in the previous 4 months, or if measles was diagnosed as the cause of death. Since the date of measles onset was not recorded, we arbitrarily assigned dates of onset as 2 months prior to the date of the visit at which measles was reported, or the date of death if the child died from measles. The season of onset of measles was classified into "dry" (November-April) or "wet" (May-October) on the basis of 1991 rainfall figures (14) . The association of measles incidence with other variables was assessed using the chi-square test of the difference between two rates (15) . Since all children in a given small geographic unit (cluster) received vitamin A (or placebo) (i.e., randomization of clusters not individuals), we compared mean incidence rates and vaccination coverage in clusters where vitamin A was administered with those where placebo was administered. We excluded three clusters from these analyses of the effect of vitamin A because they had participated in a previous vitamin A supplementation program. The trial was not designed to evaluate measles vaccine efficacy. Data on vaccination status were incomplete, and there was no clinical or laboratory confirmation of measles cases. Thus, although we obtained a crude estimate of vaccine effectiveness by comparing reported incidence rates in vaccinated and unvaccinated children, we did not conduct further analyses to assess variations with age at vaccination or time since vaccination.
Factors associated with acute fatality among measles cases. In the analysis of risk factors for acute measles fatality, we used only data on vaccination status that had been collected prior to measles onset. To have included information collected after the report of measles would have biased the results because we were unable to collect vaccination records at the verbal autopsy interview for most children who died. Anthropometric status was estimated using the weight-forage z score, compared with the National Center for Health Statistics' reference median, at the most recent visit prior to the round when measles was reported, or prior to death. Possession of a radio, bicycle, or animals by compound members and type of roof were used as indicators of socioeconomic status. Two indices of crowding were available: the number of siblings (of all ages) living in the same household and the number of children aged under 7 years in the compound. We did not collect information on the number of rooms in the compound nor on sleeping arrangements.
Univariate analyses were conducted using the chisquare test for significance, and variables that were significant at the 5 percent level were entered in multivariate analyses using EGRET (16) . A step-up logistic regression modeling procedure was followed, and variables that contributed significantly to the fit of the final model at the 5 percent level were retained in the model. We included sex in the model, although it did not contribute significantly, because of interest in sexspecific mortality (17) .
Delayed mortality after measles. To analyze delayed measles-associated mortality, we compared the survival of children who had had measles ("cases") with that of children who had not had measles ("noncases"). Because we did not have information on the exact date of measles onset, we excluded any deaths coded as measles associated from this analysis but were not able to specify a precise interval post measles at which follow-up for delayed mortality began. For each case, we attempted to select four matched controls, who were children with the same date of birth (or within 1 day) as their matching measles case, who were present during the round in which the measles case was identified, and who had the most similar identification numbers to those of the cases (identification numbers were assigned on the basis of area of residence). Controls who suffered measles during the study were excluded, but further controls were not sought. The mortality of cases and controls was compared from the round in which the measles episode of the case was reported up to the child's last home visit or the permanent out-migration of the child from the study area. Mortality rates were compared using Poisson regression and Kaplan-Meier techniques.
RESULTS

Measles vaccination
At the final survey round (September-December 1991), 61 percent of all children and 73 percent of those aged 12-23 months had a vaccination card. Forty-eight percent of all children and 62 percent of 12-to 23-month-olds had a record of measles vaccination (table 1). The median age at vaccination was 11.7 months; 22 percent of vaccinees were vaccinated before 9 months, and 15 percent, after 23 months of age. Vaccination uptake increased according to parental education and socioeconomic status, as measured by possession of a radio and zinc roofing materials, but did not vary according to sex (table 1) . Among the 182 clusters included in analyses of the effect of vitamin A, mean vaccine coverage was similar in clusters receiving vitamin A and those receiving placebo (50.3 percent and 49.7 percent, respectively).
Measles incidence
During the study period, 961 measles cases were identified, with a median age at onset of 41 months. The overall measles incidence rate was 24.3 per 1,000 child-years of follow-up. Incidence rates were highest in children aged 6-8 months, followed by those aged 9-11 months, but did not vary greatly between age 12 and 84 months (table 1). Incidence rates were similar for males and females but were higher in children from families with low paternal educational level and low socioeconomic status and in the dry season (table 1) . Areas with lower vaccination coverage had higher incidence rates (mean incidence per 1,000 child-years of 43 in areas with <40 percent coverage, 30 at 40-49 percent, 14 at 50-59 percent, and 4 at ^60 percent coverage; p < 0.01). The reported incidence was 35.5 per 1,000 child-years among unvaccinated children and 10.7 per 1,000 child-years among vaccinated children, giving a crude estimate of vaccine effectiveness of 70 percent (95 percent CI 65-74). Measles incidence was highest in January and February 1991 (figure 1) . Mean incidence was higher in clusters receiving placebo than in those receiving vitamin A (28.9 X Differences tested using chi-square test § Differences tested using test for difference between two rates and, for age, using trend test for rates. U Children were counted separately each time their vaccination status was assessed in the three annual surveys.
per 1,000 vs. 23.6 per 1,000 child-years), but this difference was not statistically significant {p = 0.33).
Acute measles case fatality
Among the 961 measles cases identified, 151 (15.7 percent) died in the acute episode. Case fatality ratios were higher among children under the age of 4 years, unvaccinated children, those whose weight-for-age was more than 2 standard deviations below the median, and cases with onset in the dry season (table 2) . Case fatality ratios were lower in children whose fathers had some education and among those with more than four siblings, but there was no difference according to the number of children under age 7 years living in the compound (not shown in the table). There were no significant differences in case fatality ratios according to sex, vitamin A supplementation prior to onset, maternal education or maternal age, compound roofing materials or compound ownership of a bicycle, or zone of residence. An effect of vitamin A prophylaxis was not seen if the analysis was restricted to children under age 2 years or to those who received at least one dose of vitamin A or placebo (date not shown). In multivariate analyses, the effects of age, vaccination status, anthropometric status, paternal education, and season of onset remained statistically significant (table 3) . 
Delayed mortality
A total of 2,662 children without measles were matched to the 810 measles cases who did not die in the acute phase (a ratio of 3.3 controls to each measles case). The median length of follow-up was only 8 months, as many measles cases (52 percent of the 810 measles cases) occurred during the last 12 months of the study. There was no significant difference in mortality between cases and controls (figure 2). Overall, there were 13 deaths among the measles cases and 36 among the children without measles, corresponding to mortality rates of 20.0 and 16.1 per 1,000 child-years, respectively (rate ratio = 1.22, 95 percent CI 0.65-2.30). Mortality rates were higher for males than females, both among children who had measles (22.7 per 1,000 child-years for boys, 16.0 per 1,000 child-years for girls) and in those without measles (17.2 per 1,000 child-years for boys, 14.8 per 1,000 child-years for girls), but these differences were not statistically significant.
DISCUSSION
This community-based study investigated the epidemiology of measles in a rural West African population with low measles vaccine coverage, where measles was estimated to account for 19 percent of all childhood deaths in the study population in 1989-1991 (13). Measles incidence showed marked seasonal and yearly variation. The average reported incidence over epidemic and nonepidemic years was rather low at around 26 per 1,000 child-years. We do not have information on the completeness of reporting of measles, and it is possible that mild measles cases in particular may have been underreported. Conversely, other rash and fever illnesses could have been reported as measles. Incidence rates were highest in families of low educational level and socioeconomic status, which were also those with low vaccination uptake. Incidence rates were highest in children aged 6-8 months, followed by those aged 9-11 months. Although measles in young infants is thought to be a predominantly urban phenomenon (18, 19) , it may be equally important in rural areas when vaccine coverage is low (20) .
Estimated measles vaccine effectiveness was low at around 70 percent. This is similar to estimates obtained from observational studies on recent outbreaks in Chad (21) and Burundi (22) , but it is lower than that obtained in serologic studies or randomized clinical trials (23) . The crude estimate, however, was subject to potential major bias from misclassification of disease and of vaccination status. Because the potential effect of such biases is large (24), we did not conduct further analyses on vaccine effectiveness.
Acute measles case fatality was high, similar to findings in unvaccinated populations in Guinea-Bissau (25) . The estimate may have been artificially high because deaths were identified through a network of informants, while detection of measles cases relied on maternal reports only. As noted previously (26) , cases in vaccinated children had a significantly reduced risk of death, and case fatality was highest in young children (2, 25, 27) . Paternal education had a greater influence on measles case fatality than did maternal education or indices of wealth. A study of maternal 1.8-6.8)  4.4(1.8-10.4)  2.6(1.2-5.7) 1.0 1.2(0.8-1.7) 1. mortality in the same area showed that the husband's educational status was more strongly associated with risk of maternal death than was the woman's educational status (28) . This may reflect the role of men as the main decision makers in this society (29) . Our study is the first to examine acute measles case fatality in relation to premorbid vitamin A supplementation. Because previous studies have suggested that vitamin A supplementation decreases measles mortality (13) and that therapeutic administration of vitamin A decreases measles case fatality (11), we were surprised to find no difference in case fatality in supplemented and unsupplemented groups. Serum retinol concentrations were higher at the end of the trial in supplemented than placebo groups (13), but vitamin A concentrations decrease during measles infection, possibly because of increased utilization of vitamin A and inadequate mobilization of hepatic stores (10, 30) . Our results suggest that vitamin A treatment of measles disease is necessary irrespective of prior supplementation.
Seasonal variation in overall child mortality is welldocumented in sub-Saharan Africa, but previous studies in rural Africa have shown mortality increases in the wet season, when there are food shortages, high food prices, high demands for agricultural work, less time for child care, and high risk of exposure to infections (31) . In urban Bamako, however, mortality rates among children under 5 years of age were three times as high at the end of the dry season (April-May) than in the cooler months of September to January, and measles incidence and mortality peaked in April (32) .
Our study was unusual in having premorbid information on anthropometric status and showed a significant increase in the measles case fatality ratio among malnourished children. There are many biologic reasons to expect more severe measles in severely malnourished children (33) , who have depressed cellmediated immunity (34), a greater risk of giant-cell pneumonia (35) , and deficient T-B lymphocyte cooperation. However, other prospective studies have shown no effect of anthropometric status on mortality (2, 25) , and anthropometric status may be confounded by intensity of exposure. Multiple cases are more likely to occur in crowded households with large fam- ilies, which are also those at risk of malnutrition (2). We did not find any association between family size and measles fatality (indeed, case fatality ratios were lower in children with five or more siblings), but we did not have precise information on the number of children per room or on the sequence of cases within households.
We did not detect increased delayed mortality after measles, unlike earlier studies in West Africa (5, 6) but in accordance with recent observations in Burundi (22) , Guinea-Bissau (36), and Senegal (37) . Some studies have shown that delayed mortality is more likely when infection occurs in the first year of life (38) . In our study, the relatively high median age at measles onset (41 months), typical of a rural area (39) , and the short median period of follow-up (8 months) resulted in only a small number of deaths in the follow-up period, which in turn led to wide confidence intervals on the estimate of the mortality rate ratio.
The most effective means to reduce measlesassociated mortality is vaccination. Reported measles vaccine coverage in Ghana reached over 60 percent after a mass campaign in 1989-1990 but subsequently fell to levels of 40-50 percent (40) . The high mortality associated with measles in Navrongo, and in other recent reports from Africa (21) , confirms the importance of long-term support to raise and sustain vaccine coverage in those populations at greatest risk of death from vaccine-preventable diseases.
